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Abstract 
 
Burkholderia pseudomallei is a Gram-negative intracellular bacterium which is 
recalcitrant to antibiotic therapy. There also is currently no licenced vaccine for this 
potentially fatal pathogen, further highlighting the requirement for better therapeutics 
to treat the disease melioidosis. Here we use an oral delivery platform, the bilosome 
to entrap already- licenced antibiotics. Bilosome-entrapped antibiotics were used to 
treat mice infected via the aerosol route with B. pseudomallei. When treatment was 
started by the oral route at 6h post-infection and continued for 7 days, bilosome 
levofloxacin and bilosome doxycycline formulations were significantly more 
efficacious than free antibiotics in terms of survival rates. Additionally, bilosome 
formulated levofloxacin protected mice from antibiotic and infection induced weight 
loss following B. pseudomallei infection.  The microbiomes of mice treated with 
levofloxacin were depleted of all phyla with the exception of Firmicutes, but 
doxycycline treatment had minimal effect on the microbiome. Encapsulation of either 
drug in bilosomes had no deleterious or clear advantageous effect on microbiome.  
This indicates that the ability of bilosomes to ameliorate antibiotic induced weight 
loss is not due to microbiome effects.  The bilosome platform not only has potential 
to reduce adverse effects of orally delivered antimicrobials, but has potential for 
other therapeutics which may cause detrimental side-effects or require enhanced 
delivery. 
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Introduction 
Burkholderia pseudomallei is an environmental pathogen and the causative agent of 
the human condition of melioidosis [1, 2]. The bacteria  survive in wet conditions 
(e.g. paddy fields) [3] with most common human exposure occurring through 
scratches or other lesions of the skin. It can cause an acute febri le illness or go 
unnoticed, depending on the inoculum size and host. The bacteria can also infect by 
the inhalational route, causing a more acute pneumonic infection. There is currently 
no licensed vaccine for melioidosis, meaning there is a heavy reliance on antibiotics 
to treat overt infection [4]. As an intracellular pathogen, B. pseudomallei has evolved 
multiple secretory and immunomodulatory mechanisms to evade innate host 
defences and to survive in granulomatous lesions for long periods. Consequently, 
this insidious pathogen is extremely difficult to access and treat effectively, limiting 
the use of antibiotics to clear the infection [5-7].  
A comparison of the minimum inhibitory concentrations (MICs) determined in vitro for 
B. pseudomallei  indicates that all the classes of antibiotics (apart from the 
aminoglycosides e.g. streptomycin/gentamicin) have some inhibitory effect on 
bacterial growth, with the combination  drug co-trimoxazole (sulfamethazole plus 
trimethoprim) looking most consistent, while  ceftazidime, ciprofloxacin and 
piperacillin have been shown to be partially effective therapies against B. 
pseudomallei [8, 9]. A potential explanation for the relative resistance of B. 
pseudomallei to multiple antibiotics is its ability to actively export antibiotics by efflux 
pumps [10]. This has a direct impact on human melioidosis where treatment is 
required initially to prevent overwhelming sepsis and mortality, with a subsequent 
prolonged oral eradication phase to kill residual bacteria. The success of this 
strategy requires a selection of antibiotics with, for example, ceftazidime and 
trimethoprin- sulphamethoxazole [11]. There is a significant risk of side effects 
arising from a lot of these combinations.   Doxycycline has been used in the past for 
treatment of localised melioidosis (and still used in some parts of the world) and 
combining  doxycycline  with another bactericidal drug  provides a  broad spectrum 
therapy for systemic disease [12, 13]. More recently however, the use of the newer 
fluoroquinolones such as levofloxacin has been expanded to include the treatment of 
other pathogens such as pneumonic plague and anthrax.   Building on this, another 
member of this class of antibiotic, finafloxacin, which has a modified structure able to 
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tolerate and retain activity in a low pH environment  such as in  a eukaryotic cell, has 
been reported to be efficacious in the treatment of experimental melioidosis [14].  
Here, we have taken the approach of encapsulating each of levofloxacin and 
doxycycline in synthetic microvesicles which have been modified for oral delivery, to 
determine if this enhances intracellular delivery/uptake and therapeutic efficacy in 
experimental melioidosis.   The synthetic microvesicles used are comprised of 
monopalmitoyl glycerol, cholesterol and the surfactant dicetyl phosphate, and thus 
are termed non-ionic surfactant vesicles (NISVs) or niosomes [15]. Furthermore, by 
the simple incorporation of bile salts, these microvesicles are converted to 
bilosomes, which are completely biocompatible and biodegradable  and provide a 
platform technology for the oral delivery of a range of  small molecules including 
hormones, proteins, DNA and vitamins [16] and now, antibiotics.  As well as 
enhancing cellular uptake [17], the physical properties of  bilosomes confer many 
other advantages including ease of modification to achieve tissue-targeted drug 
delivery [18],  increased bioavailability [19], sustained release [20], extreme stability 
in air and at temperatures up to 130oC, and are inexpensive and simple to 
synthesize, and amenable to lyophilisation [21].  
Here we report for the first time the entrapment of doxcycline and levofloxacin in 
bilosomes and the efficacy of these oral formulations in a murine post-exposure 
therapeutic model of inhalational melioidosis. We demonstrate that such formulations 
confer a statistically significant survival benefit, together with an unexpected and 
highly significant benefit in protection against infection and antibiotic-induced weight 
loss.   
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Materials and Methods 
Antibiotics 
The antibiotics, levofloxacin  +3/& and doxycycline K\FODWH 
(HPLC) (Sigma-Aldrich) were obtained in dry powder form and used in all studies.  
For making the bilosome formulations and dosing as unformulated drugs, they were 
suspended in PBS at pre-determined concentrations.  
Bacteria 
The clinical isolate Burkholderia pseudomallei K96423 was used for in vitro and in 
vivo studies. B. pseudomallei is a Containment Level 3 (Biosafety Level 3) pathogen 
that requires specialist facilities, laboratories, cabinets and isolators to carry out the 
work safely. The Defence Science and Technology Laboratory contains suites a 
number of ACDP containment level 3 (equivalent to BSL3) experimental laboratories 
with primary containment of the pathogen in double-HEPA filtered class III closed 
cabinets and ACDP CL3 animal rooms containing rigid-walled half-suit isolators for 
housing experimentally infected animals. Bacteria were grown in Luria broth at 37°C 
on a rotary platform for aerosol challenges and enumerated on L-Agar plates. 
Preparation of   bilosomes  
Bilosomes were made by the melt method. Briefly, 1-monopalmitoyl glycerol, 
cholesterol, and dicetyl phosphate in a 5:4:1 molar ratio were combined and heated 
to 130oC.   Following the addition of sodium deoxycholate in 0.025 M carbonate 
buffer and the relevant antibiotic, preparations were vortexed vigorously for 2 min. 
Antibiotics were entrapped as vesicles were formed. Non-entrapped antibiotic was 
removed through centrifugation and the pelleted vesicles re-suspended in the 
appropriate buffer containing the relevant antibiotic at a concentration equivalent to 
that entrapped within the vesicles to give a 50/50 entrapped: free preparation.   
Biophysical characterisation of bilosomes 
Large batches of bilosome preparations were formulated and aliquoted for 
lyophilisation and storage. Aliquots were recovered as required and resuspended in 
reverse osmosis water, followed by vigorous agitation.  Vesicle size and zeta-
potentials were determined using a Malvern Zeta-sizer (Zetasizer 30000HS, Malvern 
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Instruments Ltd., UK). Vesicles were pelleted by centrifugation and HPLC used to 
determine entrapped antibiotic content.  
HPLC Methodologies 
HPLC analysis was carried out on an Agilent1290 Infinity Series HPLC, using a C18 
column (150mm x 4.6mm, 5µ) maintained at 50°C. The mobile phase for both 
antibiotics (doxycycline and levofloxacin) consisted of 0.02M Na2HPO4, pH2 with 
H3PO4 and either acetonitrile or methanol.  
Dissolution Studies 
Drug release studies were carried out using a CE7smart USP-4 system (SOTAX AG, 
Switzerland) in a closed loop system with buffers being circulated at 20ml/min at 
37qC (± 1qC). Synthetic gastric fluid (SGF; 0.1M HCL, 39nM sodium taurocholate) 
and synthetic intestinal fluid (SIF; 50mM PBS, 2.171PM sodium deoxycholate pH8.5) 
was used to simulate oral delivery of the formulations. 1ml of 5mg/ml of either free 
drug or drug encapsulated in bilosomes were sealed in 300kDa dialysis membrane 
and placed in the USP-4 system. Formulations were incubated for 2 hours in SGF 
with 1ml samples being taken at 0.25, 0.5, 1 and 2 hours. The buffer was exchanged 
to SIF and 1ml samples taken at 0.25, 0.5, 1, 2, 4 and 6 hours. After sampling at 
each time point 1ml of the appropriate fresh buffer was added back into the system 
to maintain the sink volume. Sample drug concentrations were then assessed using 
HPLC (described above) and drug release expressed as cumulative milligrams over 
time elapsed.  
 
Minimum inhibitory concentrations  
MICs for antibiotic formulations were determined for B. pseudomallei strain K96243 
using the broth micro dilution method in accordance with the Clinical Laboratory 
Standards Institute (CLSI) guidelines. Assays were performed in 96 well micro-titre 
plates with antibiotic concentrations in the range of 64 mg/L to 0.03 mg/L, and 
bacteria at a final concentration of approximately 5 x 105 CFU/mL.  Following 
incubation at 37oC for 24 h the optical densities (OD) of the plates were read in an 
automated plate reader at a wavelength of 590nm.  MICs were determined as the 
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concentration that inhibited >80 % of bacterial growth via OD and confirmation by 
eye.   
Minimum bactericidal concentrations 
Minimum bactericidal concentrations (MBCs) for antibiotic formulations were 
determined by plating 100 µL aliquots of the MIC dilutions showing no visible growth 
onto L-agar plates in triplicate and incubating at 37oC for 48 hours.  The MBC was 
recorded as the lowest concentration of antibiotic that killed 99.9 % of the bacteria in 
the original inoculum.   
Microbiome and Toxicology studies : 
BALB/c mice were allocated into groups of twelve mice, and treated via the oral 
route (0.1ml/day at 10mg/ml concentration) with PBS, Empty bilosomes, 
levofloxacin, bilosome levofloxacin, doxycycline or bilosome doxycycline on days 1 
to 7.  Fecal samples were collected three days prior to treatment, 24 h. after the final 
dose (day 8) and 28 days after the cessation of treatment (dD\$QLPDOV¶ZHLJKWV
and condition were recorded daily. On day 8, half the mice in each group were 
sacrificed and serum, small intestine and large intestine were collected. Serum 
samples were stored frozen at -80°C, the large and small intestines were cleaned of 
contents, rolled into pinwheels and fixed in 10% formalin. The remaining mice were 
weighed and observed for an additional 28 days before they were sacrificed and 
serum and tissues harvested as described for the mice sacrificed on day 8.  
 
DNA Extraction and bTEFAP®: 
Genomic DNA was isolated from fecal samples using the PowerSoil® DNA Isolation 
Kit (Qiagen) following the manufacturer's instructions. As an alternative to the 
recommended 250mg of soil, approximately 200mg of fecal sample was added to 
the PowerBeads tube to undergo cell lysis. Purified DNA was eluted from the spin 
filter using 50uL of solution C6 and stored at -20°C until PCR amplification.  
The 16S universal Eubacterial primers 515F GTGCCAGCMGCCGCGGTAA and 
806R GGACTACHVGGGTWTCTAAT were uti lized to evaluate the microbial ecology 
of each sample on the HiSeq 2500 with methods via the bTEFAP® DNA analysis 
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service. Each sample underwent a single-step 30 cycle PCR using HotStarTaq Plus 
Master Mix Kit (Qiagen, Valencia, CA) were used under the following conditions: 
94°C for 3 minutes, followed by 28 cycles of 94°C for 30 seconds; 53°C for 40 
seconds and 72°C for 1 minute; after which a final elongation step at 72°C for 5 
minutes was performed. Following PCR, all amplicon products from different 
samples were mixed in equal concentrations and purified using Agencourt Ampure 
beads (Agencourt Bioscience Corporation, MA, USA). Samples were sequenced 
XWLOL]LQJ WKH,OOXPLQD +L6HTFKHPLVWU\ IROORZLQJ PDQXIDFWXUHU¶V SURWRFROV 
The Q25 sequence data derived from the sequencing was processed using a 
proprietary analysis pipeline (www.mrdnalab.com, MR DNA, Shallowater, TX).   
Sequences were depleted of barcodes and primers then short sequences < 200bp 
were removed, sequences with ambiguous base calls removed, and sequences with 
homopolymer runs exceeding 6bp removed. Sequences were then de-noised and 
chimeras removed. Operational taxonomic units (OTUs) were defined after removal 
of singleton sequences, clustering at 3% divergence (97% similarity). OTUs were 
then taxonomically classified using BLASTn against a curated 
GreenGenes/RDP/NCBI derived database and compiled into each taxonomic level 
LQWRERWK ³FRXQWV´DQG³SHUFHQWDJH´ ILOHV&RXQWVILOHVFRQWDLQ WKHDFWXDO QXPEHURI
sequences while the percent files contain the relative (proportion) percentage of 
sequences within each sample that map to the designated taxonomic classification.   
Statistical analysis was performed using a variety of computer packages including 
XLstat 1&66  ³5´ DQG 1&66   $OSKD DQG EHWD GLYHUVLW\ DQDO\VLV ZDV
conducted as described previously using Qiime (www.qiime.org).  
 
Animal Infection Studies: 
Six to eight week old female BALB/c mice (Charles River, UK) were transferred to a 
high containment Class III rigid isolator, where they were given unlimited access to 
food and water and allowed to acclimatise for at least 5 days. Mice were allocated to 
treatment groups (15 per group) and housed in cages of 5. Mice were challenged 
with 50-100 CFU (10MLD) of B. pseudomallei K96243 via the aerosol route in a 
nose-only exposure system using a computerised delivery platform (Biaera 
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Technologies). A sub-optimal therapy study design was used, in which antibiotic 
administration was started at 6h post-infection and administered orally once daily for 
only 7 days, to  test therapeutic efficacy. The treatment groups comprised bilosome-
formulated antibiotics or unformulated antibiotics.   The antibiotics levofloxacin, 
doxycycline, bilosome encapsulated levofloxacin and bilosome encapsulated 
doxycycline were delivered daily by the oral route at 50mg/kg and treatment was 
continued for 7 days. A subgroup of 5 mice per treatment group was culled at day 3 
p.i. to determine bacterial loads in lung, spleen and liver. All mice were checked 
twice daily and scored for clinical signs and mice were weighed daily. Mice reaching 
a humane end-point, based on a pre-determined set of objective clinical signs, were 
promptly culled. Survival times were recorded for some mice and others were culled 
for analysis of tissues at different time points. All procedures and housing complied 
with the UK Animal (Scientific Procedures) Act (1986). 
 
Statistical Analysis: 
Drug release profiles between free and encapsulated drug were compared using the 
f2 similarity test in accordance to the FDA guidelines (Appendix II of the "Note for 
Guidance on the investigation of bioavailability and bioequivalence". If the f2 score is 
less than 50 then the formulation being tested is considered to be dissimilar to the 
reference control [22]. A variety of statistical analyses have been performed using the 
program SPSS V21.0 (IBM) or Graphpad PRISM V6.0. Graphs have been constructed using 
Graphpad PRISM V6.0. Survival data were compared using log rank tests. Continuous data 
were analysed by parametric analysis (ANOVA, T tests, GLM) when conditions were met 
(QQ SORWVWRDVVHVV*DXVVLDQGLVWULEXWLRQDQG/HYHQH¶V%DUWOHWWWHVWVIRUXQHTXDOYDULDWLRQ
or non-parametric tests (Kruskal-Wallis, Mann-Whitney, Moods) where these criteria were 
not met. In some cases it was possible for parametric criteria to be attained in the use of 
transformations such as logarithmic transformation.  Contingency tables were used for 
binary data. Multiple testing corrections for familywise error were performed on individual 
FRPSDULVRQVZLWKDQDO\VHV7KHVHLQFOXGHG%RQIHUURQL¶VDQG'XQQ¶s corrections. 
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Results 
Entrapment of antibiotics into bilosomes.  
The bilosome formulation technology was adapted to successfully entrap the 
fluoroquinolone levofloxacin and the tetracycline doxycycline. The total antibiotic 
delivered by each formulation in mg/ml, together with percentage of this which was 
entrapped, is recorded in Table 1.  For each formulation, more than 50% of the total 
antibiotic was entrapped. The mean size of bilosomes with antibiotic cargo was in 
the range 2700 -3400 nm with zeta potentials in the range of ±30 to -23, where 
negative values for zeta potential indicate formulation stability.  
Assessment of formulation stability.  
The stability (determined via Zeta potential) of the bilosome formulations was tested 
as freeze-dried preparations at a range of temperatures (room temperature, +4oC 
and -20oC) and at a range of time post- manufacture (1 week, 1 month and 3 
months) (Table 2). The bilosome zeta potential remained relatively consistent across 
all time points and all temperatures. There was slight variability in the bilosome 
doxycycline formulation if kept at room temperature, however all formulations used in 
these studies were stored at -20 oC and used within a month of manufacture.  
 
Dissolution studies  
Release profiles of encapsulated drug were studied in a system to simulate oral 
delivery and to compare the dissolution of bilosome encapsulated and free drug 
controls. Bilosome encapsulation of levofloxacin modestly reduced dissolution rate 
over the first 2 hours compared with free drug when incubated in synthetic gastric 
fluid (SGF).  However, the vast majority of both levofloxacin formulations had been 
releases by 2 hours. Following buffer exchange to SIF the remaining levofloxacin 
was released by the end of the 8 hour study. Free levofloxacin and bilosome 
levofloxacin release profiles were found to be dissimilar SGF using the f2 similarity 
test gave (score: 48.8) (Figure 1). For doxycycline formulations the free drug 
displayed a rapid dissolution profile over the 2 hours in SGF medium with all of the 
5mg being released. In comparison bilosome encapsulated doxycycline had a 
dissimilar, slower release profile (score: 15.56) with only 2.2mg of the doxycycline 
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being released into the SGF. Doxycylcine continued to be released from the 
bilosome formulation in the SIF over the remaining 6 hours resulting in a cumulative 
total of 2.9mg being released (score 14.89 for the cumulative release in SGF and 
SIF) (Figure 1). 
 
In vitro assessment of bilosome formulations for minimum inhibitory 
concentrations (MIC) and minimum bactericidal concentrations (MBC). 
To rule out the possibility that the formulation of antibiotics in bilosomes would 
adversely affect antimicrobial function, the MICs and MBCs of the formulations were 
tested in vitro  against  B. pseudomallei.  In each of these assays, bilosome-
formulated antibiotics exerted as much antimicrobial activity as unformulated 
antibiotics, indicating that the process of formulation had not adversely affected the 
antibiotic cargo (Table 3).  
Safety/ toxicology studies on   bilosome formulations  
Since the bilosome antibiotic formulations are novel, a repeat- dose murine 
safety/toxicology study was also carried out to evaluate the tolerability of the 
formulations.  
In these specific toxicology studies, the effects of treatment with two different 
antibiotics, formulated in either saline or bilosomes, were evaluated on weight gain, 
microbiome composition, small intestine histology and serum serotonin levels 
(therapeutic efficacy is discussed later).  Levofloxacin or doxycycline were given 
orally for seven days, and half the mice were sacrificed on day 8 to evaluate the 
immediate impact of treatment.  Faecal pellets were collected from mice sacrificed at 
day 8.  The remaining mice were monitored for 28 days after the cessation of 
treatment, with faecal pellets collected at day 22 and terminal samples collected on 
day 36.   No mortality was noted, small intestine histology was normal in all animals, 
and there were no statistically significant differences between groups in serum 
serotonin levels (data not shown). 
However statistically significant differences in weight gain were noted between 
treatment groups (Figure 2). In particular the bilosome levofloxacin group lost 
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significantly less weight than mice treated with unformulated levofloxacin at days 14 
and 36 post treatment (p<0.05). Interestingly therapy ended at d7 indicating that the 
bilosome formulation increases the recovery phase. No significant difference was 
seen between bilosome doxycycline and free doxycycline treated groups. 
 
Microbiome analysis  
To investigate the ability of bilosomes to ameliorate antibiotic-induced weight loss, 
the gut microbiome of mice was monitored prior to antibiotic treatment and 8 days 
following treatment and analysed .by 16s RNA  sequencing. A total of fifty-nine (59) 
genera were defined as high frequency (present in at least 75% of specimens). 
There was some variation in the presence of these 59 genera in the baseline 
samples, but at least 57 genera were present in all groups. A total of eighty-one (81) 
genera were defined as low frequency (present in less than 25% of specimens). No 
more than 15 of these 81 genera were present in any one group at any time point, 
with most genera being absent from most specimens. In total, these genera 
accounted for very little of the total microbial complement.  The results demonstrate 
that bilosomes had no adverse effects on the microbiome (Figure 3). 
Formulation of levofloxacin with bilosomes did not protect the vast majority of the 
microbiome in treated mice. All phyla of bilosome formulated levofloxacin and free 
levofloxacin treated mice, with the exception of the Firmicutes were reduced to 
minimal levels following treatment as observed on day 8 (Figure 3). However, within 
the Firmicutes, only subtle differences were noted in the genera maintained in the 
bilosome  levofloxacin  mice, compared with the free levofloxacin treated mice 
(Figure 3).  
 
Doxycycline treatment had less severe effects on host microbiome, irrespective of 
formulation as determined on day 8. Mice treated with free doxycycline or bilosome 
doxycycline all had similar levels of Firmicutes and Bacteriodetes as observed in 
mice pre-treatment, although mice given doxycycline in bilosomes had an increased 
ratio of Firmicutes to Bacterioidetes.  No significant differences were noted between 
animals treated with PBS over the course of the study.  The ratio of Firmicutes to 
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Bacteriodetes was increased in mice treated with empty bilosomes compared with 
the same animals before commencing treatment (Figure 3). Minor phyla with the 
exception of Actinobacteria were greatly diminished in groups of animals at day 8 
post infection (Figure 3).  
By day 36 of the experiment (4 weeks post treatment), bacteriodetes levels had 
recovered in levofloxacin and levofloxacin in bilosome treated animals to pre-
treatment levels. All groups of animals including control PBS treated had some 
Verrucomicrobia present at this timepoint. Levels of minor phyla including 
Spirocaetae, Tenericutes, Actinobacteria and Proteobacteria had also recovered to 
pre-treatment levels at this time point (Figure 3).   
 
 
In vivo Assessment of bilosome formulations to treat B. pseudomallei 
infection 
The efficacy of bilosome formulations of levofloxacin and doxycycline was tested in 
an aerosol model of melioidosis, using a  sub-optimal therapy study design, in which 
antibiotic administration was started at 6h post-infection and administered once daily 
for only 7 days, to test therapeutic efficacy. The treatment groups comprised 
bilosome-delivered antibiotics or unformulated antibiotics, with control groups 
receiving PBS or empty bilosomes. This study was repeated twice with exactly the 
same design, conditions and identical treatment groups, the data were stratified and 
combined for analysis, to give an overall significant survival advantage for bilosome-
encapsulated versus free levofloxacin (p=0.014) with an average survival rate of 90% 
vs 55% and a median survival for both the PBS and empty bilosome controls of d4 p.i 
(Median survival for levofloxacin and bilosome levofloxacin is undefined) (Figure 4). A 
significant survival advantage for bilosome-encapsulated versus free doxycycline was 
also seen (p<0.001). An average survival rate of 40% vs 0% was recorded with 
median survival for both the PBS and empty bilosome controls of d4 p.i, doxycycline 
was d6 p.i and bilosome doxycycline d10 p.i (Figure 5).  
In addition to the survival advantage conferred by delivering levofloxacin in 
bilosomes, over free levofloxacin, bilosome levofloxacin- treated groups lost 
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significantly less body weight compared to levofloxacin (Figure 6). In the levofloxacin 
treatment groups, the protection against antibiotic-induced weight loss in mice 
receiving the bilosome formulations, was very marked, such that the combined data 
from the bilosome±levofloxacin treated groups gave a highly significant difference in 
weight loss (p<0.001, Figure 6).  No difference in weight loss between bilosome 
doxycycline and free doxycycline groups was noted, but this was due to the majority 
of free doxycycline mice succumbing to infection before antibiotic dosing was 
completed (Figure 7).  
Bacteriological, immunological and blood chemistry analyses show supporting but 
non-significant changes between bilosome and free antibiotic- treated groups. At d.3 
p.i., cytokine analysis of lung, spleen and liver tissue samples showed a decrease in 
pro-inflammatory cytokines in bilosome levofloxacin treated groups and this 
correlated with a reduction in ALT and GGT, enzymes associated with liver damage  
(data not shown). 
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Discussion 
The emergence of antimicrobial resistance in a number of clinically important 
bacteria along with the natural ability of microbes to evade treatment is a continuing 
concern [23, 24]. It is well documented that there has been a lack of investment in 
new antimicrobial therapies and thus repurposing or re-formulation of already 
licensed drugs is a potentially attractive solution [25]. Encapsulation of therapies to 
improve delivery and access to  intracellular niches is a developing area both 
academically and industrially [26].  For these reasons, we reformulated two existing 
antibiotics, levofloxacin and doxycycline and utilised a mouse model of melioidosis to 
determine their efficacy. Treatment options for B. pseudomallei are not always 
completely effective and this intransigent pathogen has been documented in one 
extreme case to persist in a person and emerge 60 years after the original exposure 
[27]. Current suggested clinical treatment of melioidosis consists of two phases. 
Phase 1 is administration of Ceftazidime or Meropenem via the intravenous route 
followed by an elongated Phase 2 where Trimethoprim-sulfamethoxazole or 
Amoxicillin/clavulanic acid (co-amoxiclav) are administered orally for several months 
[28-30]. Other antibiotic combinations have been explored clinically, including the 
use of doxycycline and ciprofloxacin [31, 32]. Therefore the optimisation of oral drug 
delivery is of importance for melioidosis treatment and many other pathogens (e.g. 
biothreat agent) where treatment is difficult or inappropriate. 
 Liposome encapsulation of various drugs including antibiotics has been explored for 
decades and has shown promise [33]. Indeed encapsulation of ciprofloxacin has 
been demonstrated to reduce bacterial load and increase survival of mice infected 
with Francisella tularensis, Coxiella burnetti or Yersinia pestis [34-37].  However, 
less literature is available regarding NISVs, despite their many perceived advantages 
over liposomes, including their enhanced stability, simpler formulation and cheaper 
synthesis [16, 21, 38]. However, recent reports demonstrate the successful 
encapsulation of ciprofloxacin in NISV (comprising a range of nonionic surfactants) 
and demonstrate the drug maintains in vitro efficacy against the Gram-positive 
Staphylococcal aureus (40.41). 
In these studies, we demonstrate that NISVs stabilised with bile salts for oral delivery 
as bilosomes are suitable platforms for two antibiotics, a tetracycline and a 
fluoroquinolone. Formulated drugs had improved dissolution profi les with both 
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levofloxacin and doxycycline release being prolonged in synthetic gastric fluid. This 
was particularly striking in the doxycycline formulation. The formulations generated 
are stable and retain antimicrobial activity in vitro. In vivo data suggests that 
bilosome vesicular formulations of both levofloxacin and doxycycline have increased 
efficacy in a murine model against B. pseudomallei.  Thus mice receiving these 
formulations had significantly increased survival rates and time, compared to those 
receiving non-encapsulated drugs. 
The data presented here show that the freeze-dried formulations generated are 
stable and that the encapsulation process has not impaired the antimicrobial activity 
of the cargo when tested in vitro. Both bilosome formulations had the same MIC and 
MBC values against B. pseudomallei and F. tularensis (Francisella data not shown) 
as free antibiotic. This was expected as the concentration of the antibiotic acting on 
the bacterial pathogen is the same irrespective of how it was formulated. The 
advantages of encapsulation as envisaged in an in vivo infection model, such as 
slower release and targeting, would not be seen in the in vitro MIC assay employed.  
Stability of adapted and/or novel therapeutic formulations is of increasing interest. 
This is especially important for distribution to low/middle income countries where 
cold storage may not be readably available. Previous work in our laboratory has 
shown that both NISV and bilosome formulations can be freeze dried and maintain 
entrapment efficiency for 6 months at room temperature.  Other measures of stability 
such as, size and charge of vesicles were also shown to be relatively consistent over 
time in our studies and are similar to previous reports where NISVs were stored for 
90 days [39, 40]. Further interesting studies have demonstrated the ability of NISVs 
to enhance the photo-stability of compounds entrapped [41]. This again would be an 
added advantage for NISVs and bilosomes as delivery platforms.  
Despite the obvious benefits of antibiotics, side effects  can occur, especially 
associated with repeated dosing over a long duration. Indeed it is well documented 
that antibiotics from the fluoroquinolone family cause significant side effects including 
weight loss  [42]. This is most likely due to the antibiotic disturbing the gut microbiota 
and altering the digestive tract [43]. Herein we demonstrated that entrapment of 
levofloxacin in bilosomes ameliorates antibiotic- induced weight loss in mice.  
Further, we have found that the formulation of ciprofloxacin in NISVs or bilosomes 
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protected against antibiotic-induced weight loss (data not shown). Bilosome 
doxycycline showed no change in weight loss compared to controls. This may be 
attributed to the different properties of this tetracycline compound, compared to the 
fluoroquinolones, including its bacteriostatic, rather than bactericidal effects. 
Further, when the antibiotic dosing regimen was used to treat B. pseudomallei 
infection, the protection against weight loss was pronounced in the bilosome 
levofloxacin treated groups. Indeed it has previously been reported that NISV can 
protect from weight loss induced by FK-565, an experimental anti-tumour drug and 
also during an infection setting, where NISVs have been shown to protect against 
Toxoplasma gondii induced weight loss during vaccination studies (Patent No. 
CA2228298A1).  
Other perceived advantages of vesicular delivery include altering PK/PD of 
therapeutic compounds, such as cancer agents [44]. To date, we have observed 
only minor changes in PK/PD with these antibiotics, but since levofloxacin and 
doxycycline are in any case highly bioavailable drugs, there is less potential benefit 
of encapsulation on PK/PD.  
To determine whether there was a therapeutic advantage of encapsulation of 
antibiotics in bilosomes it was necessary to uti lise a sub-optimal antibiotic model 
where we know that free levofloxacin or doxycycline would not totally clear B. 
pseudomallei infection. Despite starting our therapy early (6 hours post-infection) the 
concentration of levofloxacin and doxycycline used were below those previously 
reported to clear infection [45, 46].   
The survival rate and time of Burkholderia-infected mice were significantly increased 
when treated with bilosome formulated levofloxacin or doxycycline rather than free 
drug. The increases in protection seen from the bilosome formulations were not 
directly related to pathogen clearance at early time points as determination of 
bacterial loads showed no significant difference between treatment groups. The lack 
of bactericidal differences between vesicle formulated antibiotic and free antibiotic 
seen in our studies may be due to the route of administration and/or the fact that we 
are using different antibiotics. Identification of the full mechanism of protection 
associated with the bilosome platform is underway. It was initially hypothesised that 
the mechanism of protection could be related to difference in the effects of each drug 
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formulation on the microbiome. It is well documented that changes in the microbiome 
can alter systemic immunity [47, 48]. Indeed a recent paper it has demonstrated that 
disrupting the gut microbiome with a broad cocktail of antibiotics prior to infection 
with Burkholderia increased growth and dissemination of the bacteria systemically, 
including changes in the lung [49]. In our studies we saw only minor differences in 
the microbiomes of mice treated with entrapped and free antibiotic formulations.  
Additional in- depth analyses needs to be carried out, but preliminary data would 
suggest that the advantages seen with the bilosome formulation are not solely 
related to changes in the microbiome.  
There are many methods of NISV preparation which can alter the characteristics of 
the vesicles and therefore make them highly adaptable for numerous uses [50]. The 
method used for these studies was the melt method [51], where the 3 components  
are heated  to high temperature  then  mixed  with  PBS containing antibiotic.  Other 
methods such as ether injection, Ph gradient and micro- fluidisation have all been 
used and shown to be suitable to generate NISVs [52-54] and we have also 
automated and scaled-up production to achieve controlled batch consistency. NISVs 
have also been shown to have a variety of applications including vaccine platforms, 
delivery of anticancer or anti-parasitic drugs [51, 55-57]. Further adaptations of the 
vesicles make them suitable for crossing the blood brain barrier [58, 59]. 
 
Overall, the data reported here support bilosomes as a broad platform technology for 
the delivery of antibiotics. This technology not only provides a significant survival 
advantage in the infection models examined, but also reduces the serious side effect 
of weight loss associated with repeated antibiotic dosing and infection. Therefore 
there is potential that this drug delivery system would have uti lity in a biothreat 
scenario where drugs would most likely be delivered orally as a post exposure 
prophylaxis [60]. The precise mechanism responsible for this protection will need 
further investigation. 
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Table 1: Total loading, percentage entrapment and zeta potential of Bilosomes 
formulations  
The values presented in the table are generated from making bilosomes via the melt 
method with entrapped concentrations determined via HPLC following removal of 
free antibiotic. Size and zeta potential measurements were determined by a Malvern 
Zeta-sizer and data are presented as raw values for 3 independent samples. Means 
and SEM are highlighted. 
Antibiotics 
Formulations 
Total 
antibiotic in 
formulation 
(mg/ml) 
Antibiotic 
entrapped in 
formulation 
(mg/ml) 
Percentage 
entrapped 
(%) 
Size 
Zeta 
Potential 
(mV) 
Bilosome 
Levofloxacin 19.4 11.4 58.9 
2846.0 
±124.42 
-29.667 
±0.31 
Bilosomes 
Doxycycline 17.2 9.2 53.5 
3329.33 
±85.62 
-23.33  
±0.29 
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Table 2:  Stability of   bilosomes with time and storage conditions, as 
measured by zeta potential 
Bilosome antibiotic formulations were made as previously described and 
subsequently freeze dried (FD). Formulations were left at a variety of different 
storage temperature (37oC, Room Temperature, 4oC or -20oC) and assayed at 
multiple time points post manufacture (1 week, 1 month and 3 months) to determine 
the zeta potential of the vesicles. FD formulations were rehydrated at each time point 
for the assay. Measurements were determined by a Malvern Zeta-sizer and data are 
presented as raw values (zeta potential) for 3 independent samples per time point 
and per storage conditions. Means and SEM are highlighted in bold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Storage 
Time 
Bilosome Formulation 
Levofloxacin Doxycycline 
RT 4°C -20°C RT 4°C -20°C 
Start 
-28.10 
 
 
-19.80 
 
 
-30.20 
 
 
-22.60 
 
 
-32.70 
 
 
-27.80 
 
 
Mean -30.33 N/A N/A -23.40 N/A N/A 
SEM 0.42 
 
 
0.74 
 
 
1 Week 
-24.40 -28.90 -17.90 -24.00 -28.30 -28.10 
26.10 -31.90 -18.00 -30.00 -27.90 -25.90 
25.90 -31.50 -19.00 -27.30 -26.50 -28.50 
Mean -25.47 -30.77 -18.30 -27.10 -27.57 -27.50 
SEM 0.17 0.30 0.11 0.55 0.17 0.26 
1 Month 
-24.20 -26.5 -29.80 -16.50 -26.70 -22.20 
26.30 -30.00 -30.20 -18.40 -28.2 -22.80 
-28.00 -31.00 -32.70 -18.70 -30.00 -26.50 
Mean -26.17 -29.17 -30.90 -17.87 -28.30 -23.83 
SEM 0.35 0.43 0.29 0.22 0.30 0.43 
3 Month 
-28.90 -29.90 -26.00 -35.3 -23.40 -33.6 
29.40 -30.9 -28.50 -36.4 28.10 -36.40 
29.20 -32.60 -27.90 -37.00 29.00 -35.00 
Mean -29.17 -31.13 -27.47 -36.23 -26.83 -35.00 
SEM 0.05 0.25 0.24 0.16 0.55 0.26 
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Table 3 In vitro assessment of antimicrobial properties of formulated 
antibiotics by determination of Minimum Inhibitory concentrations (MIC) and  
Minimum bactericidal concentrations (MBC) 
Values represented on the table are the median value generated from 3 independent 
experiments with 3 technical repeats in each experiment. MIC is the lowest 
concentration that inhibits growth i.e. Value is recorded when growth is less than 
10% of positive control. Measured by OD. MBC is the lowest concentration that 
prevents 99.9% of positive control growth i.e. No bacterial colonies present from 10µl 
drops on agar plates. 
Antibiotic Formulation Burkholderia pseudomallei K96243 
 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
Free Levofloxacin 2 32 
Bilosome Levofloxacin 4 8 
Free Doxycycline 1 16 
Bilosome Doxycycline 1 16 
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Figures and Figure Legends 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Cumulative drug release profiles using USP-4 for free and bilosome 
encapsulated Levofloxacin or Doxycycline. SGF buffer was used for the first 2 
hours and exchanged to SIF for the remaining 6 hours of the study. Buffers were 
circulated at 20ml/min at 37qC (± 1qC). Drug concentrations were determined by 
HPLC. Results are from an N=3 ± SEM and plotted as cumulative mg of drug 
released. 
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Figure 2 
 
 
Figure 2: Weight change following daily dosing with antibiotic formulations. 
Groups of 10 mice were dosed daily with 0.1 ml (at a concentration of 1mg per 
mouse) of each antibiotic. Bilosome formulations were administered by the oral 
route. Suitable controls (free antibiotic in PBS) were included for all groups. Mice 
were weighed daily and data recorded as percentage change from starting weight. 
Control panel compares PBS treated to empty bilosome treated. The levofloxacin 
and Doxycycline panels compare free drug to bilosome formulated. (* p<0.05)   
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Figure 3 
 
 
Figure 3: Broad Microbiome analysis following treatment with antibiotic 
formulations 
Genus data was categorised into specific phyla to which they belong and percentage 
abundance for each treatment group was calculated. Data was graphed on area 
charts/stacked bar charts + SE. Major Phyla (Verucomicrobia, Bacteriodetes and 
Firmicutes) presented on top panel with minor phyla (Spriochaetae, Tenericutes, 
Actinobacteria and Proteobacteria) presented at the bottom. PBS = Phosphate 
buffered saline, EB = Empty Bilosomes, L = Levofloxacin, LB = Levofloxacin 
Bilosomes, D = Doxycycline and DB = Doxycycline Bilosomes. 
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Figure 4 
 
 
Figure 4: Bilosome levofloxacin comparison to free levofloxacin in an aerosol 
model of B. pseudomallei. Data represented on the graphs are Kaplan Meier plots, 
with 10 mice per group. Experiment 1 (top left panel), Experiment 2 (top right panel) 
and combined stratified data (bottom panel). PBS and Empty Bilosome treatment 
groups were included as controls. 
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Figure 5 
 
 
)LJXUH%LORVRPHGR[\F\FOLQHFRPSDULVRQWRIUHHGR[\F\FOLQHLQDQDHURVRO
PRGHORI%SVHXGRPDOOHL'DWDUHSUHVHQWHGRQWKHJUDSKVDUH.DSODQ0HLHUSORWV
ZLWKPLFHSHUJURXS([SHULPHQWWRSOHIWSDQHO([SHULPHQWWRSULJKWSDQHO
DQG FRPELQHG VWUDWLILHG GDWD ERWWRP SDQHO 3%6 DQG (PSW\ %LORVRPH WUHDWPHQW
JURXSVZHUH LQFOXGHGDVFRQWUROV 
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Figure 6 
 
 
)LJXUH$QLPDOZHLJKWGDWDIROORZLQJH[SRVXUHWRDQDHURVROFKDOOHQJHRI %
SVHXGRPDOOHLDQGWUHDWPHQWZLWK OHYRIOR[DFLQRU%LORVRPHOHYRIOR[DFLQ'DWD
UHSUHVHQWHGDUHSORWVIRULQGLYLGXDOPLFH([SHULPHQWWRSOHIWSDQHO([SHULPHQW
WRSULJKWSDQHO &RPELQHGGDWDFRPSDULQJ OHYRIOR[DFLQDQG%LORVRPHOHYRIOR[DFLQ
XVHV ER[ DQG ZKLVNHU SORWV ZLWK ,QWHU 4XDUWLOH 5DQJHV ERWWRP SDQHO 3%6 DQG
(PSW\ %LORVRPH WUHDWPHQW JURXSV ZHUH LQFOXGHG DV FRQWUROV EXW RPLWWHG LQ WKH
FRPELQHGDQDO\VLV 
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Figure 7 
 
 
)LJXUH$QLPDOZHLJKWGDWDIROORZLQJH[SRVXUHWRDQDHURVROFKDOOHQJHRI %
SVHXGRPDOOHL DQG WUHDWPHQW ZLWK GR[\F\FOLQH RU %LORVRPH GR[\F\FOLQH'DWD
UHSUHVHQWHGDUHSORWVIRULQGLYLGXDOPLFH([SHULPHQWWRSOHIWSDQHO([SHULPHQW
WRSULJKWSDQHO&RPELQHGGDWDFRPSDULQJ OHYRIOR[DFLQDQG%LORVRPHGR[\F\FOLQH
XVHV ER[ DQG ZKLVNHU SORWV ZLWK ,QWHU 4XDUWLOH 5DQJHV ERWWRP SDQHO 3%6 DQG
(PSW\ %LORVRPH WUHDWPHQW JURXSV ZHUH LQFOXGHG DV FRQWUROV  EXW RPLWWHG LQ WKH
FRPELQHGDQDO\VLV 
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Graphical abstract 
Highlights 
x Bilosomes are Non-Ionic Surfactant Vesicles suitable for oral delivery 
x Bilosomes have been shown to  entrap the antibiotics ciprofloxacin and doxycycline  
x Bilosomes increase antibiotic efficacy in a Burkholderia model of infection 
x Bilosomes can protect against antibiotic and infection induced weight loss 
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